Minaris has developed TESSA, a novel self-silencing helper adenoviral vector system designed for high-yield, contaminant free AAV manufacturing in serum-free suspension HEK293 cells.
Minaris Advanced Testing provides Minaris AgentSCREENa GMP-qualified Next Generation Sequencing (NGS) platform that simplifies adventitious agent testing with a predictable 28-day turn-around time, regulatory aligned workflow, and U.S. based end-to-end support.
Overview of analytical services including biosafety testing, viral clearance, stability studies, and GMP lot release for biologics and advanced therapies.
The page explains that a robust quality control release testing protocol is essential for launching a successful GMP program for biologics, ensuring products meet scientific specifications and reach patients safely.
LVV manufacturing efficiency is limited by auto-transduction, which reduces viral yield. Minaris identified an Additive X that minimizes this loss, enhancing upstream production and enabling higher-titre LVV for emerging in vivo therapies.
NGS enables precise analysis of AAV and lentiviral vectors by assessing payload integrity, stability, and homogeneity. Minaris introduces bioinformatics pipelines for QC, variant detection, transcript validation, and splicing characterization.
Minaris evaluates whether XOFLX LVV production can be further improved using high-density cell culture and extended multi-harvest strategies to boost overall yield.
Minaris' TESSA platform uses a self-silencing helper adenoviral vector to block late structural protein expression, enabling a scalable, cost-effective and clean AAV manufacturing process without adenoviral contamination.
Minaris Advanced Therapies' Japan site is first company officially listed on FIRM's Japanese Industrial Standard (JIS) Q 2101 Self-Declaration Registry.
The page describes the peer-reviewed TESSA technology publication in *Molecular Therapy*, highlighting its role in advancing clinical methods and development.
XOFLX stable cell lines and packaging systems enable high-yield, cost-effective lentiviral vector manufacturing, as detailed in a *Molecular Therapy* study.
Minaris Advanced Testing traces its history from virology to dedicated laboratories in Philadelphia, offering audit-ready quality control for cell and gene therapies and biologics.
The page offers quote requests, order placement, and access to the MATOS portal for routine and custom biosafety testing, including sample submission support.
Minaris is a cell & gene therapy CDMO exclusively serving advanced therapies, with biosafety testing services for biologics, mAbs, vaccines, and CGT developers.
The company publishes guidelines on transparency in relationships with medical institutions, including its stance, disclosure methods, timelines, and categories of funding such as clinical research and non-clinical research costs.
Oxford Genetics Limited (“Licensor”) grants the customer (“Licensee”) a limited, non-exclusive, non-transferable, revocable license to use the SnapFast Plasmids (Plasmids) solely for Research Purposes and solely in accordance with this LULL. All rights not expressly granted are reserved by Licensor.